Abstract Number: 0304 • ACR Convergence 2023
Incidence of Disease Flares Following COVID-19 Vaccination in a Diverse Idiopathic Inflammatory Myopathy Cohort
Background/Purpose: Autoimmune activation in the setting of vaccination against coronavirus disease 2019 (COVID-19) is a well-documented phenomenon in the medical literature. For patients with idiopathic…Abstract Number: 1297 • ACR Convergence 2023
COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Rheumatoid Arthritis: Results from the COVAD Study
Background/Purpose: COVID-19 vaccines have been proven to be safe in the healthy population. Data on longer-term AEs in people with autoimmune diseases (AIDs), including rheumatoid…Abstract Number: 1813 • ACR Convergence 2023
Assessing Immunogenicity of SARS-CoV-2 Vaccine Neoantigen S1 in Autoimmune Rheumatic Disease Patients: A Study on Cellular and Humoral Responses
Background/Purpose: Data on cellular and humoral immunogenicity triggered by SARS-CoV-2 vaccines in patients with autoimmune rheumatic diseases (ARD) are limited. While current vaccine efforts have…Abstract Number: 2131 • ACR Convergence 2023
Time-course Analysis from the First Wave to Early 2023 in Critically Ill Patients with Novel Coronavirus Infection in Rheumatoid Arthritis
Background/Purpose: We analyzed trends in the incidence and severity of novel coronavirus disease (COVID-19) from the first wave to early 2023 in patients with rheumatoid…Abstract Number: 0215 • ACR Convergence 2023
Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort
Background/Purpose: Vaccine platforms, number of doses, and immunosuppressive drugs can influence the immunogenicity after SARS-CoV-2 vaccination in individuals with immune-mediated rheumatic diseases. Considering the heterogeneity…Abstract Number: 0412 • ACR Convergence 2023
COVID Antibody Response to Third Dose Anti-SARS-COV2 mRNA Vaccine in Patients with Seropositive Rheumatoid Arthritis on Immunosuppressive Therapy
Background/Purpose: Patients with immune-mediated inflammatory diseases on immunosuppressive medications are presumed to be at increased risk for hospital admissions and deaths related to COVID-19 infections.…Abstract Number: 1450 • ACR Convergence 2023
Clinical Manifestations and Outcomes in Systemic Lupus Erythematosus Patients Who Received Antiviral Therapy During the COVID-19 Omicron Variant Wave: Results from a Single Center Cohort of Puerto Rico
Background/Purpose: The impact of COVID-19 in patients with systemic lupus erythematosus (SLE) has been a subject of great concern. Antiviral therapy has emerged as a…Abstract Number: 1815 • ACR Convergence 2023
The Association of Body Mass Index with SARS-CoV-2 Infection (COVID-19) in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Background/Purpose: To determine the association of body mass index (BMI) with incident COVID-19 infection in patients with inflammatory arthritis (IA) using biologic disease-modifying anti-rheumatic drugs…Abstract Number: 2159 • ACR Convergence 2023
Results of a 24-week Open-label, Non-interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis After Switching from Anti-B-cell Therapy During the SARS-COV-2 Pandemic
Background/Purpose: The COVID-19 pandemic has significantly changed the understanding of the safety profile of therapies for immunoinflammatory rheumatic diseases. This is primarily due to the…Abstract Number: 0216 • ACR Convergence 2023
High Immunogenicity of mRNA Covid-19 Vaccine Booster in Immune Mediated Inflammatory Disease
Background/Purpose: Patients with immune-mediated inflammatory disorders (IMIDs) have an inherently heightened susceptibility to infection and may be considered high risk for COVID-19, yet IMID populations…Abstract Number: 0446 • ACR Convergence 2023
Review of Rheumatoid Arthritis Treatment Landscape During the COVID-19 Pandemic
Background/Purpose: During the COVID-19 pandemic, guidelines were amended with respect to the prescribing of biologic/tsDMARD usage to treat rheumatoid arthritis (RA). In addition, regulatory reviews…Abstract Number: 1470 • ACR Convergence 2023
SARS-CoV-2 Antibody Formation After COVID-19 Vaccination in SLE Patients Treated with Belimumab: Single-Center Prospective Observational Study
Background/Purpose: Patients with systemic lupus erythematosus (SLE) should be more proactive with the administration of the COVID-19 vaccine, as their systemic conditions are prone to…Abstract Number: 1822 • ACR Convergence 2023
The Food and Drug Administration’s (FDA’s) Safety Surveillance of Baricitinib and Tocilizumab for COVID-19 (Disclaimer: This Abstract Reflects the Views of the Authors and Not Necessarily Those of the US FDA)
Background/Purpose: Baricitinib, a Janus kinase inhibitor, and tocilizumab, an interleukin-6 receptor antagonist, are two products first approved for the treatment of rheumatoid arthritis. Notably, these…Abstract Number: 2268 • ACR Convergence 2023
Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study
Background/Purpose: Poor COVID-19 outcomes in patients with systemic lupus erythematosus (SLE) has been found to be associated with glucocorticoid dose, male sex, older age, mycophenolate,…Abstract Number: 0217 • ACR Convergence 2023
Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study
Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 38
- Next Page »